Q1 2026 Devyser Diagnostics AB Earnings Call Transcript
Key Points
- Devyser Diagnostics AB (STU:OL0) reported a positive EBIT for the fourth consecutive quarter, indicating a successful focus on profitable growth.
- The company achieved a 24% growth in fixed currencies, outpacing the market.
- Gross margin improved to 82%, surpassing the full year 2025 margin, reflecting effective cost management.
- The acquisition of Cybergene is expected to strengthen Devyser's commercial position and contribute positively to gross profit and margin.
- A significant agreement with Illumina was signed, providing opportunities for reagent rental in the European market, which is expected to drive future growth.
- EMEA reported slower growth in Q1, indicating regional performance fluctuations.
- The ongoing conflicts in the Middle East have impacted distributor sales, although the company managed to ship according to plan.
- There is uncertainty regarding the timing and impact of orders from Thermo Fisher, affecting revenue visibility.
- The MolDX application for a post-transplant kidney test in the US is still pending, with approval expected by year-end, creating uncertainty in market expansion.
- The reagent rental model with Illumina may result in lower margins in the short term, despite potential for increased top-line sales.
Welcome to Devyser Diagnostics Q1 report 2026 Presentation. (Operator Instructions) Now I will hand the conference over to the speakers. CEO, Jan Wahlstrom; and CFO, Sabina Berlin. Please go ahead.
Good morning, and welcome to the Devyser Q1 2026 earnings call. My name is Jan Wahlstrom, I'm the CEO of Devyser and would like to thank you, everyone, for joining our call today. On the call today, we have, in addition to myself, also our CFO, Sabina Berlin.
I will start with a short summary of highlights from the quarter before handing over to Sabina for a more detailed review of our financial results with January to March, and then we'll go through an update on our recent commercial activities.
First quarter came in with a positive EBIT, the fourth consecutive quarter in a row. As you know, we started the journey in the beginning of last year, focusing on the company towards profitable growth. It's been a successful journey, and we're happy to deliver a strong growth and positive
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
